The COVID-19 vaccine developed by Vaxine has now received a marketing authorisation from the Iranian FDA for children aged 5 years and above. This follows a successful clinical trial where the vaccine was tested in children between 5 and 18 years of age and was shown to be safe and effective in inducing neutralizing antibodies against the SARS-CoV-2 virus. This approval follows on from an approval in Jan 2023 where it was given a marketing authorisation for use as a booster dose following a primary course of any COVID-19 type, meaning that people who have had side effects to one of the other COVID-19 vaccines can now chose to switch to our highly safe and non-reactogenic protein based alternative.